Research
William Blair Downgrades Cardiff Oncology to Market Perform From Outperform
Cardiff Oncology (CRDF) has an average rating of overweight and mean price target of $6.21, according to analysts polled by FactSet.
$CRDF
$CRDF
7 stories mentioning CRDFUpdated 32d ago
Every FINWIRES story that references CRDF, newest first.
What are analysts saying about CRDF?
Recent broker actions mentioned in FINWIRES coverage. Compiled from wire headlines; not investment advice.
What's the latest news on CRDF?
Insider Trading
Cardiff Oncology Insider Bought Shares Worth $1,000,000, According to a Recent SEC Filing
Gary W Pace, Director, on July 14, 2026, executed a purchase for 687,285 shares in Cardiff Oncology (CRDF) for $1,000,000. Following the Form 4 filing with the SEC, Pace has control over a total of 2,043,661 common shares of the company, with 2,043,661 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1213037/000119312526306083/xslF345X05/ownership.xml
$CRDF
Sectors
Sector Update: Healthcare Stocks Fall Late Afternoon
Healthcare stocks declined late Monday afternoon, with the NYSE Healthcare Index falling 1.4% and the State Street Health Care Select Sector SPDR ETF (XLV) dropping 1.1%.The iShares Biotechnology ETF (IBB) shed 1.4%.In corporate news, Cardiff Oncology (CRDF) shares tumbled past 21% after HC Wainwright downgraded the stock to neutral from buy, and TD Cowen to hold from buy.GRAIL (GRAL) stock dropped 9.7% after the company said the NHS-Galleri trial of its Galleri multi-cancer early detection test missed its primary endpoint.Jasper Therapeutics (JSPR) shares tumbled 32% after the firm said its board has launched a review of strategic alternatives, including a sale of assets, a sale of the company, merger, or an orderly wind-down of operations.Edgewise Therapeutics (EWTX) has agreed to sell its muscular dystrophy business to Servier for up to $2.65 billion, Servier said Monday. Edgewise shares jumped past 13%.
$CRDF$EWTX$GRAL$JSPR
Sectors
Sector Update: Healthcare
Healthcare stocks declined late Monday afternoon, with the NYSE Healthcare Index falling 1.4% and the State Street Health Care Select Sector SPDR ETF (XLV) dropping 1.1%.The iShares Biotechnology ETF (IBB) shed 1.4%.In corporate news, Cardiff Oncology (CRDF) shares tumbled 22% after HC Wainwright downgraded the stock to neutral from buy, and TD Cowen downgraded the stock to hold from buy.
$CRDF
Wire
Cardiff Oncology Shares Fall After HC Wainwright, TD Cowen Downgrades
Cardiff Oncology (CRDF) shares fell 23% in Monday trading after HC Wainwright downgraded the stock to neutral from buy.TD Cowen downgraded the stock to hold from buy.Intraday volume topped 5.21 million shares, compared with the daily average of 781,884.Price: $1.46, Change: $-0.44, Percent Change: -23.16%
$CRDF
Research
TD Cowen Downgrades Cardiff Oncology to Hold From Buy
Cardiff Oncology (CRDF) has an average rating of overweight and mean price target of $8.36, according to analysts polled by FactSet.
$CRDF
Research
HC Wainwright Downgrades Cardiff Oncology to Neutral From Buy
Cardiff Oncology (CRDF) has an average rating of buy and mean price target of $8.36, according to analysts polled by FactSet.
$CRDF
